MedTrace Logo

Autologous Transplantation for Multiple Myeloma

NCT00378222 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2006-09-19

No results posted yet for this study

Summary

The present study was designed in an attempt to prospectively evaluate in a randomized fashion whether further cytotoxic dose intensification, as delivered with two sequential autologous stem-cell transplantations, improved the outcome of younger patients with newly diagnosed multiple myeloma in comparison with a single autologous transplantation.

Conditions

Interventions

PROCEDURE

Autologous Stem Cell Transplantation

Sponsors & Collaborators

  • University of Bologna

    lead OTHER

Principal Investigators

  • Michele Cavo, MD · Institute of Hematology and Medical Oncology - University of Bologna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Completion
2005-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00378222 on ClinicalTrials.gov